human growth hormone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-26 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
==== Hovertrain ==== Early in 1973, rumours began to circulate that the Tracked Hovercraft (known as the "Hovertrain"), a planned 300 mph floating train on which work had begun in 1967, was to be cancelled. On 12 February 1973, Heseltine gave a written answer on Peter Walker's behalf to a written question from Labour MP David Stoddart, that a further injection of government money was still "under consideration". However, two days later Heseltine appeared before the Select Committee, and revealed that the government had already decided to pull the plug on the Hovertrain on 29 January. Airey Neave believed Heseltine had been lying and urged Stoddart to pursue the matter. The Hovertrain incident came to be regarded as the worst example of lying to the House of Commons since the Profumo affair a decade earlier, and Heseltine survived because full details only emerged during the Parliamentary summer recess. The committee's report in September accused Heseltine of having given an "untrue" answer on 12 February. Heseltine immediately gave a press conference (7 September 1973) in which he denied that he had lied. On the orders of Chief Whip Francis Pym he apologised to the House of Commons on 16 October 1973 for having made a statement which was open to "more than one interpretation".
The hypothalamic–pituitary–thyroid axis plays a key role in maintaining thyroid hormone levels within normal limits. Production of TSH by the anterior pituitary gland is stimulated in turn by thyrotropin-releasing hormone (TRH), released from the hypothalamus. Production of TSH and TRH is decreased by thyroxine by a negative feedback process. Not enough TRH, which is uncommon, can lead to insufficient TSH release and therefore insufficient thyroid hormone production. Pregnancy leads to marked changes in thyroid hormone physiology. The gland increases in size by 10%, thyroxine production increases by 50%, and iodine requirements increase. Many women have normal thyroid function but have immunological evidence of thyroid autoimmunity (as evidenced by autoantibodies) or are iodine-deficient, and develop evidence of hypothyroidism before or after giving birth.
== Background == Porous inorganic solids have found great utility as catalysts and sorption media because of their large internal surface area, i.e. the presence of voids of controllable dimensions at the atomic, molecular, and nanometer scales. With increasing environmental concerns worldwide, nanoporous materials have become more important and useful for the separation of polluting species and the recovery of useful ones. In recent years there has been great progress in applying environmentally friendly zeolites in heterogeneous reaction catalysis. The reason for their success is related to their specific features in converting molecules having kinetic diameter below 1 nm, but they become inadequate when reactants with sizes above the dimensions of the pores have to be processed. Research efforts to synthesize zeolites with larger pore diameter, high structural stability and catalytic activity have not given the expected results yet.
== Peroxisomal beta-oxidation == Fatty acid oxidation also occurs in peroxisomes when the fatty acid chains are too long to be processed by the mitochondria. The same enzymes are used in peroxisomes as in the mitochondrial matrix and acetyl-CoA is generated. Very long chain (greater than C-22) fatty acids, branched fatty acids, some prostaglandins and leukotrienes undergo initial oxidation in peroxisomes until octanoyl-CoA is formed, at which point it undergoes mitochondrial oxidation. One significant difference is that oxidation in peroxisomes is not coupled to ATP synthesis. Instead, the high-potential electrons are transferred to O2, which yields hydrogen peroxide. The enzyme catalase, found primarily in peroxisomes and the cytosol of erythrocytes (and sometimes in mitochondria), converts the hydrogen peroxide into water and oxygen. Peroxisomal β-oxidation also requires enzymes specific to the peroxisome and to very long fatty acids. There are four key differences between the enzymes used for mitochondrial and peroxisomal β-oxidation:
=== Common names === Common names for B. edulis vary by region. The standard Italian name, porcino (pl. porcini), means porcine; fungo porcino, in Italian, echoes the term suilli, literally "hog mushrooms", a term used by the Ancient Romans and still in use in southern Italian terms for this species. The derivation has been ascribed to the resemblance of young fruit bodies to piglets, or to the fondness pigs have for eating them. It is also known as "king bolete". The English penny bun refers to its rounded brownish shape. The German name Steinpilz (stone mushroom) refers to the species' firm flesh. In Austria, it is called Herrenpilz, the "noble mushroom", while in Mexico, the Spanish name is panza, meaning "belly". Another Spanish name, rodellon, means "small round boulder", while the Dutch name eekhoorntjesbrood means "squirrel's bread". Russian names are belyy grib (ru:белый гриб; "white mushroom" as opposed to less valuable "black mushrooms") and borovik (ru:боровик; from bor—"pine forest"). The vernacular name cep is derived from the Catalan cep or its French name cèpe, although the latter is a generic term applying to several related species. In France, it is more fully cèpe de Bordeaux, derived from the Gascon cep "trunk" for its fat stalk, ultimately from the Latin cippus "stake". Ceppatello, ceppatello buono, ceppatello bianco, giallo leonato, ghezzo, and moreccio are names from Italian dialects, and ciurenys or surenys is another term in Catalan. The French-born King Charles XIV John popularised B.
Sources: en.wikipedia.org
=== Cysteine and cystine === As the functional group of the proteinogenic amino acid cysteine, the thiol group plays a very important role in biology. When the thiol groups of two cysteine residues (as in monomers or constituent units) are brought near each other in the course of protein folding, an oxidation reaction can generate a cystine unit with a disulfide bond (−S−S−). Disulfide bonds can contribute to a protein's tertiary structure if the cysteines are part of the same peptide chain, or contribute to the quaternary structure of multi-unit proteins by forming fairly strong covalent bonds between different peptide chains. A physical manifestation of cysteine-cystine equilibrium is provided by hair straightening technologies. Sulfhydryl groups in the active site of an enzyme can form noncovalent bonds with the enzyme's substrate as well, contributing to covalent catalytic activity in catalytic triads. Active site cysteine residues are the functional unit in cysteine protease catalytic triads. Cysteine residues may also react with heavy metal ions (Zn2+, Cd2+, Pb2+, Hg2+, Ag+) because of the high affinity between the soft sulfide and the soft metal (see hard and soft acids and bases). This can deform and inactivate the protein, and is one mechanism of heavy metal poisoning.
== Adverse effects == The adverse side effects of amphetamine are many and varied, and the amount of amphetamine used is the primary factor in determining the likelihood and severity of adverse effects. Amphetamine products such as Adderall, Vyvanse, and their generic equivalents are currently approved by the U.S. FDA for long-term therapeutic use. Recreational use of amphetamine generally involves much larger doses, which have a greater risk of serious adverse drug effects than dosages used for therapeutic purposes.
P3 peptides are thought to have a role in neuronal death and in the enhanced inflammatory response in AD and DS, as it has been demonstrated that the treatment of cells with the p3 fragment, induced by the c-Jun N-terminal kinases (JNK) phosphorylation, is involved in neuronal cells apoptosis and causes the death of SH-SY5Y and IMR‐32 human neuroblastoma cells.
Caffeine can produce a mild form of drug dependence – associated with withdrawal symptoms such as sleepiness, headache, and irritability – when an individual stops using caffeine after repeated daily intake. Tolerance develops to autonomic effects (blood pressure, heart rate, nervousness) and to alerting/vigilance benefits with regular use. Chronic exposure upregulates adenosine receptors, raising the effort threshold for allocating attention—even to mundane or previously enjoyable tasks—because habitual users operate from a lowered arousal baseline. Caffeine is classified by the US Food and Drug Administration (FDA) as generally recognized as safe. Lethal doses, over 10 grams per day for an adult, greatly exceed the typical dose of under 500 milligrams per day. The European Food Safety Authority reported that up to 400 mg of caffeine per day (around 5.7 mg/kg of body mass per day) does not raise safety concerns for non-pregnant adults, while intakes up to 200 mg per day for pregnant and lactating women do not raise safety concerns for the fetus or the breast-fed infants. A 6 ounce cup of coffee typically contains 50–175 mg of caffeine, depending on what "bean" (seed) is used (and how much), how it is roasted, and how it is prepared (e.g., drip, percolation, or espresso). Thus roughly 50–100 ordinary cups of coffee would be required to reach a lethal dose. However, pure powdered caffeine, which is available as a dietary supplement, can be lethal in tablespoon-sized amounts.
The Samoyed tail is one of the breed's distinguishing features. Like the Alaskan Malamute, the tail is carried curled over the back; however, unlike the Alaskan Malamute, the Samoyed tail is held actually touching the back. It is not usually held in a tight curl, or held flag-like; it is usually carried lying over the back and to one side. In cold weather, Samoyeds may sleep with their tails over their noses to provide additional warmth. Almost all Samoyeds will allow their tails to fall when they are relaxed and at ease, as when being stroked or while eating, but will return their tails to a curl when more alert. Samoyeds have a dense, double layer coat. The topcoat contains long, coarse, and straight guard hairs, which appear white but have a hint of silver coloring. This top layer keeps the undercoat relatively clean and free of debris. The under layer, or undercoat, consists of a dense, soft, and short fur that keeps the dog warm. The undercoat typically sheds heavily once or twice a year, and this seasonal process is sometimes referred to as "blowing coat". This does not mean the Samoyed will shed only during that time however; fine hairs (versus the dense clumps shed during seasonal shedding) will be shed all year round, and have a tendency to stick to cloth and float in the air. The standard Samoyed may come in a mixture of biscuit and white coloring, although pure white and all biscuit dogs are common. Males typically have larger ruffs than females. While this breed is touted as "hypoallergenic", it does shed a fair amount and needs frequent grooming.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.